Please login to the form below

Jounce

This page shows the latest Jounce news and features for those working in and with pharma, biotech and healthcare.

GSK discontinues two feladilimab trials in head and neck cancer

In November 2020, Jounce Therapeutics also announced that it would not expand a phase 2 trial of its own ICOS-targeting monoclonal antibody vopratelimab after revealing less-than-stellar results.

Latest news

Celgene cuts back Jounce alliance ahead of BMS merger

Despite the thinning down of the alliance, the news was greeted enthusiastically by Jounce investors, with its shares rising more than 30% on Wednesday. ... Jounce must now deliver positive results from its phase 2 EMERGE clinical trial of vopratelimab
Bluebird and Celgene BCMA CAR-T kicks off ASCO

That includes data on Jounce Therapeutics’ ICOS-targeting antibody JTX-2011 which disappointed investors when the ASCO abstract was made public earlier this month, as well as Celldex’ anti-CD27 agonist
Immuno-oncology at ASCO: survival data, combinations and new indications

Standout examples of that this year include Jounce Therapeutics - which fell dramatically after data from a phase I trial of its ICOS agonist antibody JTX-2011 alongside Bristol-Myers Squibb’s
Celgene pays $300m upfront for immunology start-up Delinia

$43.5m and a $2.5bn licensing deal with Jounce for five immuno-oncology candidates.
Jounce bags $225m upfront in Celgene immuno-oncology deal

Celgene has bolstered its immuno-oncology pipeline in an agreement with US biotech Jounce Therapeutics that gives it options on five experimental cancer therapies. ... According to Jounce Celgene was one of several companies trying to close a licensing

More from news
Approximately 2 fully matching, plus 4 partially matching documents found.

Latest Intelligence

Deal Watch July 2016

Licensee. Licensor. Headline. Upfront. Equity. Near-term R&D funding. Celgene. Jounce. $2, 561m. ... Jounce Therapeutics/ Celgene. Portfolio and platform of biomarker driven immuno-oncology therapeutics and CDx.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest appointments

Hugh Cole joins Jounce Therapeutics as chief business officer

US clinical-stage pharmaceutical company Jounce Therapeutics has appointed Hugh Cole as its new chief business officer and head of corporate development. ... We are thrilled to welcome him to Jounce at a critical point in our drug development process.”.
Constellation Pharmaceuticals appoints Jigar Raythatha as CEO

Raythatha re-joins the firm from Jounce Therapeutics where he was chief business officer, leading its business strategy and development since December 2012.
Merck’s Richard Murray joins Jounce as CEO

pembrolizumab. This experience will benefit Jounce, a Cambridge, Massachusetts-based company that specialises in cancer immunotherapies. ... The new CEO sees potential in Jounce, however, with the prospect of cancer immunotherapies an appetising one for